Pasar al contenido principal

ANALISIS FUNCIONAL DE LA NUEVA RUTA DE SEÑALIZACION TOR4-AMPK QUE REGULA LA DIFERENCIACION DE FORMAS INFECTIVAS PROLIFERATIVAS A QUIESCENTES EN TRYPANOSOMA BRUCEI

SAF2015-71444-P

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei

  • Pham, ThanhTruc
  • Walden, Madeline
  • Butler, Christopher
  • Díaz-González, Rosario
  • Pérez-Moreno, Guiomar
  • Ceballos-Pérez, Gloria
  • Gómez-Pérez, Veronica
  • García-Hernández, Raquel
  • Zecca, Henry
  • Krakoff, Emma
  • Kopec, Brian
  • Ichire, Ogar
  • Mackenzie, Caden
  • Pitot, Marika
  • Ruiz-Pérez, Luis Miguel
  • Gamarro, Francisco
  • González-Pacanowska, Dolores
  • Navarro, M.
  • Dounay, Amy B.
In 2014, a published report of the high-throughput screen of>42,000 kinase inhibitors from GlaxoSmithKline against T. brucei identified 797 potent and selective hits. From this rich data set, we selected NEU-0001101 (1) for hit-to-lead optimization. Through our preliminary compound synthesis and SAR studies, we have confirmed the previously reported activity of 1 in a T. brucei cell proliferation assay and have identified alternative groups to replace the pyridyl ring in 1. Pyrazole 24 achieves improvements in both potency and lipophilicity relative to 1, while also showing good in vitro metabolic stability. The SAR developed on 24 provides new directions for further optimization of this novel scaffold for anti-trypanosomal drug discovery., Boettcher Foundation's Webb-Waring Biomedical Research Program; Boettcher Collaboration Grant; Research Corporation Cottrell College Science Award; National Institute of Allergy and Infectious Diseases (US):R01AI114685; Ministerio de Economia, Industria y Competitividad (España) SAF2015-71444-P; SAF2015-68042-R; SAF2016-79957-R; Junta de Andalucia CTS-7282; Subdireccion General de Redes y Centros de Investigacion Cooperativa (RICET) RD16/0027/0019, DG-P RD16/0027/0014; NSF-MRI CHE-1429567, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis

  • Tear, WF
  • Bag S
  • Díaz-González, Rosario
  • Ceballos-Pérez, Gloria
  • Rojas-Barros, Domingo I.
  • Cordon-Obras, Carlos
  • Pérez-Moreno, Guiomar
  • García-Hernández, Raquel
  • Martínez-Martínez, María S.
  • Ruiz-Pérez, Luis Miguel
  • Gamarro, Francisco
  • González-Pacanowska, Dolores
  • Caffrey, Conor R.
  • Ferrins, Lori
  • Manzano, Pilar
  • Navarro, M.
  • Pollastri, Michael P.
From a high-throughput screen of 42 444 knownhuman kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold wasidentified to begin optimization for the treatment of human Africantrypanosomiasis. Previously reported data for analogous com-pounds against human kinases GSK-3β, CDK-2, and CDK-4 wereleveraged to try to improve the selectivity of the series, resulting in23awhich showed selectivity forT. b. bruceiover these threehuman enzymes. In parallel, properties known to influence theabsorption, distribution, metabolism, and excretion (ADME)profile of the series were optimized resulting in20gbeingprogressed into an efficacy study in mice. Though20gshowedtoxicity in mice, it also demonstrated CNS penetration in a PKstudy and significant reduction of parasitemia in four out of the sixmice., This work was supported by National Institutes of HealthGrants (R01AI114685 (M.P.P. and M.N.), R01AI082577(M.P.P.), R56AI099476 (M.P.P.), R01AI124046 (M.P.P.),R21AI127594 (M.P.P.), the Spanish Ministerio de Economía,Industria y Competitividad (M.N., Grant SAF2015-71444-P;D.G.P., Grant SAF2016-79957-R., and Subdirección Generalde Redes y Centros de Investigación Cooperativa (RICET)(M.N., Grant RD16/0027/0019; D.G.P., Grant RD16/0027/0014), Grant RTI2018-097210-B-100 (MINCIU-FEDER) toF.G. C.R.C. acknowledges grant support from the NIH-NIAID(Grant R21AI126296) and the Bill and Melinda GatesFoundation (Grant OPP1171488), as well as the technicalassistance of Brian M. Suzuki for screening adultS. mansoni.We are grateful to AstraZeneca for performing thein vitroADME experiments presented throughout and to CharlesRiver Labs for thein vitroADME data presented inTables S3−S5 in the Supporting Information. We thank GSK Tres Cantosopen lab foundation for running the PK studies discussed inthis publication. An academic license for ChemAxon (https://www.chemaxon.com) is gratefully acknowledged. We thankDr. Melissa Buskes for help in the preparation of thismanuscrip
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacophore identification and structure-activity relationship analysis of a series of substituted azaindoles as inhibitors of Trypanosoma brucei

  • Ferrins, Lori
  • Díaz, Rosario
  • Cordon-Obras, Carlos
  • Rojas-Barros, Domingo I.
  • Quotadamo, Antonio
  • Oehme, Daniel P.
  • Ceballos-Pérez, Gloria
  • Swaminathan, Uma
  • Pérez-Moreno, Guiomar
  • Bosch-Navarrete, Cristina
  • García-Hernández, Raquel
  • Gómez-Liñán, Claudia
  • Saura, Andreu
  • Ruiz-Pérez, Luis Miguel
  • Gamarro, Francisco
  • Martínez-Martínez, María S.
  • Manzano, Pilar
  • González-Pacanowska, Dolores
  • Navarro, Miguel
  • Pollastri, Michael P.
Human African trypanosomiasis is among the World Health Organization’s designated neglected tropical diseases. Repurposing strategies are often employed in academic drug discovery programs due to financial limitations, and in this instance, we used human kinase inhibitor chemotypes to identify substituted 4-aminoazaindoles, exemplified by 1. Structure–activity and structure–property relationship analysis, informed by cheminformatics, identified 4s as a potent inhibitor of Trypanosoma brucei growth. While 4s appeared to be fast acting and cidal in the in vitro assays, it failed to cure a murine model of infection. Preliminary efforts to identify the potential mechanism of action of the series pointed to arginine kinase, though, as we demonstrate, this does not appear to be the sole target of our compounds. This comprehensive approach to drug discovery, encompassing cheminformatics, structure–potency and structure–property analysis, and pharmacophore identification, highlights our multipronged efforts to identify novel lead compounds for this deadly disease., The authors acknowledge funding from the National Institute of Allergy and Infectious Diseases (M.P.P., M.N., and D.G.-P., R01AI114685; M.P.P., R21AI127594 and R01AI124046), the Spanish Ministerio de Ciencia, Innovación y Universidades, (D.G-P., Grant PID2022-142971OB-I00, funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; M.N., SAF2015-71444), the Subdirección General de Redes y Centros de Investigación Cooperativa (RICET) (M.N., RD16/0027/0019; D.G.-P., RD16/0027/0014), RTI2018-098834-B-I00 (MINCIU-FEDER) to M.N., and RTI2018-097210-B-I00 (MINCIU-FEDER) to F.G., Peer reviewed